Tenderwize
Wróć do wyszukiwania

Open-house rebate agreement for Relugolix

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Nov 03, 2027 · 432 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Relugolix, ATC L02BX04

62/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

62 / 100

Złożoność

58 / 100

Czynniki ryzyka

Submitting documents through the wrong portal area is explicitly prohibited; the contract documents must be sent via th...

The latest contract conclusion date is 03.11.2027, and monthly cut-offs apply for next-month start dates.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Dec 2027
  • Non-exclusive open-house rebate agreements for the active substance Relugolix, ATC L02BX04.
  • Supply of pharmaceutical products under a pre-defined contract model with no individual negotiation.
Pokaż pełne podsumowanie

Open-house supply arrangement for pharmaceutical products concerning Relugolix (ATC L02BX04) by AOK Bayern. The model is explicitly described as non-exclusive and open to all interested pharmaceutical companies that meet the stated suitability requirement. No estimated contract value is provided. Submission is via DTVP electronic portal with a qualified electronic signature or by paper originals in duplicate; the latest contract conclusion date is 03.11.2027, while the overall contract period runs from 01.01.2026 to 31.12.2027.

Ryzyka

Submitting documents through the wrong portal area is explicitly prohibited; the contract documents must be sent via th...

The latest contract conclusion date is 03.11.2027, and monthly cut-offs apply for next-month start dates.

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • Submit a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
  • Submit the completed and signed contract and the completed and signed annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open-house rebate agreement for Relugolix

Single lot for non-exclusive open-house rebate agreements for the medicinal product Relugolix, ATC L02BX04. Scope is pharmaceutical supplies in Germany (place of performance: DE212 / Bavaria). The lot information comes from structured data and XML notice text.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Dec 2025 - Dec 2027

Kategoria

Pharmaceutical products

Termin

Deadline Nov 03, 2027

Szczegóły zamówienia

Data publikacji
16 Nov 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
761915-2025

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30